|
 
- 现金
- 13255 元
- 精华
- 9
- 帖子
- 7621
- 注册时间
- 2003-11-5
- 最后登录
- 2012-12-19
|
1楼
发表于 2008-10-20 10:50
科学家称：判断肝癌患者能否被治愈的关键或许不是在肝脏肿瘤本身，而在于肿瘤周围看似健康的肝细胞。
一个跨国研究小组表示，他们发现，肿瘤周围组织的186种基因物质的活跃程度决定了肝细胞癌变是否还会复发。
哈佛大学和麻省理工学院癌症项目小组负责人托德·戈卢布（Todd R. Golub）博士表示，预测癌变是否还会发生的关键讯息并非在癌症肿瘤本身，而是临近的非肿瘤性肝组织。
“被损坏的肝脏事实上会生长出新的肿瘤，同时已经生出的肿瘤会慢慢恢复，”戈卢布说。
新的研究报告登载在《新英格兰医学杂志》（New England Journal of Medicine）上。该研究成果有望帮助医生判断是否需对术后患者采用积极的治疗措施。
 
N Engl J Med. 2008 Oct 15. [Epub ahead of print]
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma.
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR.
From the Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA (Y.H., D.Y.C., A.C., S.G., J.M., M.J.W., J.L., M.R., J.A.C., S.G., T.R.G.); Howard Hughes Medical Institute (T.R.G.), Dana-Farber Cancer Institute (Y.H., D.Y.C., T.R.G.), and Brigham and Women's Hospital (J.N.G.), Harvard Medical School, Boston; Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York (A.V., J.P., S.R., M.S., S.T., S.L.F., J.M.L.); Toranomon Hospital, Tokyo (M.K., K.I., M.H., G.W., H.K.); National Cancer Institute, Milan (M.G.D., V.M.); Haukeland University Hospital, University of Bergen, Bergen, Norway (H.B.S.); and Barcelona Clinic Liver Cancer Group, Institut d'Investigacions Biomediques August Pi i Sunyer Centro de Investigaciónes en Red de Enfermedades Hepáticas y Digestivas Hosptial Clínic Barcelona (J.B., J.M.L.) and Institució Catalana de Recerca i Estudis Avancats (J.M.L.) - both in Barcelona. This article (10.1056/NEJMoa0804525) was published at www.nejm.org on October 15, 2008. It will appear in the November 6 issue of the Journal.
BACKGROUND: It is a challenge to identify patients who, after undergoing potentially curative treatment for hepatocellular carcinoma, are at greatest risk for recurrence. Such high-risk patients could receive novel interventional measures. An obstacle to the development of genome-based predictors of outcome in patients with hepatocellular carcinoma has been the lack of a means to carry out genomewide expression profiling of fixed, as opposed to frozen, tissue. METHODS: We aimed to demonstrate the feasibility of gene-expression profiling of more than 6000 human genes in formalin-fixed, paraffin-embedded tissues. We applied the method to tissues from 307 patients with hepatocellular carcinoma, from four series of patients, to discover and validate a gene-expression signature associated with survival. RESULTS: The expression-profiling method for formalin-fixed, paraffin-embedded tissue was highly effective: samples from 90% of the patients yielded data of high quality, including samples that had been archived for more than 24 years. Gene-expression profiles of tumor tissue failed to yield a significant association with survival. In contrast, profiles of the surrounding nontumoral liver tissue were highly correlated with survival in a training set of tissue samples from 82 Japanese patients, and the signature was validated in tissues from an independent group of 225 patients from the United States and Europe (P=0.04). CONCLUSIONS: We have demonstrated the feasibility of genomewide expression profiling of formalin-fixed, paraffin-embedded tissues and have shown that a reproducible gene-expression signature correlated with survival is present in liver tissue adjacent to the tumor in patients with hepatocellular carcinoma.
[ 本帖最后由 张医生 于 2008-10-20 13:06 编辑 ] |
|
